Low-Dose Naltrexone and Gabapentin Interaction: What Women Need to Know

The Short Answer: Can You Take Low-Dose Naltrexone With Gabapentin?

You can take both drugs at the same time, but the combination is not risk-free. No direct metabolic drug-drug interaction exists between LDN and gabapentin, because neither drug is meaningfully processed through the cytochrome P450 (CYP) enzyme system. The risk that does exist is pharmacodynamic: both agents depress the central nervous system (CNS), and their sedating effects add together. For women, this matters because hormonal fluctuations across the menstrual cycle, perimenopause, and postmenopause alter baseline CNS sensitivity and renal clearance, two of the main variables that determine how hard this combination hits.

Why Women Are Prescribed Both Drugs Together

Women make up the majority of patients with fibromyalgia, with prevalence estimates of roughly 7 women for every 1 man affected. Endometriosis affects approximately 10 percent of reproductive-age women globally. Both conditions are frequently managed with gabapentin off-label for pain modulation. LDN is increasingly prescribed off-label for the same inflammatory and pain conditions. A woman with fibromyalgia or endometriosis who is already on gabapentin for pain might be offered LDN to reduce systemic inflammation, making this combination clinically common even if it has not been formally studied as a pair.

What Each Drug Does at the Receptor Level

Understanding the interaction requires knowing what each drug is actually doing inside your body.

Low-dose naltrexone is a mu-opioid receptor antagonist at standard doses (50 mg) used in alcohol use disorder. At the much lower doses used off-label (1.5 to 4.5 mg), the proposed mechanism shifts. LDN transiently blocks opioid receptors for a few hours, which appears to trigger a rebound upregulation of endogenous opioid signaling and, separately, to antagonize toll-like receptor 4 (TLR4) on microglial cells, reducing neuroinflammation. A 2013 pilot trial by Younger et al. In fibromyalgia patients demonstrated a 30 percent reduction in pain scores with 4.5 mg LDN versus placebo, providing the most cited controlled evidence for LDN in this population.

Gabapentin was originally developed as a GABA analogue but does not actually bind GABA receptors directly. It binds the alpha-2-delta subunit of voltage-gated calcium channels in the dorsal horn of the spinal cord and in the brain, reducing excitatory neurotransmitter release. This calcium-channel modulation is responsible for both the analgesic and the sedating effects.

The Pharmacokinetic Picture: Why CYP Enzymes Are Not the Issue

Neither LDN nor gabapentin is metabolized by CYP3A4, CYP2D6, or any other major hepatic cytochrome P450 enzyme. This is actually the reason the combination is even considered: the hepatic interaction risk is minimal.

How LDN Is Processed

Naltrexone at all doses is rapidly absorbed after oral administration and undergoes extensive first-pass hepatic metabolism, but the enzyme responsible is ketone reductase (not CYP), converting naltrexone to its active metabolite 6-beta-naltrexol. The FDA label for naltrexone 50 mg confirms that the drug is not a substrate or inhibitor of CYP enzymes, and this applies equally to compounded low-dose formulations. Neither drug will alter the other's plasma concentration by competing for hepatic enzymes.

How Gabapentin Is Processed

Gabapentin is handled even more simply. It is not metabolized at all. The drug is absorbed from the gut via a saturable amino acid transporter (LAT1), circulates unchanged in plasma, and is excreted entirely by the kidneys as unchanged drug. The gabapentin prescribing information notes a half-life of 5 to 7 hours and linear excretion proportional to creatinine clearance. No hepatic interaction is possible.

The Renal Overlap: Where Both Drugs Compete

This is the underappreciated risk. Both drugs depend on renal clearance. Naltrexone's active metabolite 6-beta-naltrexol is renally excreted. Gabapentin is entirely renally excreted. In a woman with normal kidney function (eGFR above 60 mL/min/1.73 m2), clearance of both drugs proceeds without accumulation. If eGFR drops below 60, both drugs can accumulate, increasing CNS exposure and the risk of excessive sedation.

Women's renal function is influenced by hormonal status in ways that are often overlooked. Estrogen has renal-protective effects, and the drop in estrogen at menopause is associated with accelerated decline in GFR. A 2019 analysis in the American Journal of Kidney Diseases found that postmenopausal women had significantly faster GFR decline compared to premenopausal women of similar age. This makes postmenopausal women a group that warrants renal function review before combining these two renally cleared drugs.

The Pharmacodynamic Risk: Additive CNS Depression

This is the main clinical concern. Both LDN and gabapentin act centrally, and their sedating effects add together even without a pharmacokinetic interaction.

Gabapentin's CNS Depression Profile

Gabapentin produces dose-dependent sedation, dizziness, and ataxia. At doses above 1,800 mg per day, a meaningful proportion of patients report significant somnolence. The 2019 FDA safety communication on gabapentinoids noted cases of serious respiratory depression, particularly in patients with underlying respiratory compromise, those using CNS depressants concurrently, and older adults. While LDN is not a classical opioid and does not cause respiratory depression on its own at low doses, the additive CNS load in a patient with sleep apnea, obesity, or other risk factors may be clinically relevant.

LDN's CNS Profile at Low Doses

LDN at 1.5 to 4.5 mg produces transient opioid blockade lasting approximately 4 to 6 hours after a nightly dose. Some women report vivid dreams or mild sleep disruption during the first 2 to 4 weeks, which is distinct from sedation. At LDN doses, clinically meaningful respiratory depression has not been reported in the published literature. The CNS depression contribution from LDN alone is small, but it is not zero in a susceptible individual.

Clinical Severity Rating

Standard drug interaction databases (Lexicomp, Micromedex) classify the gabapentin and naltrexone combination as moderate severity, with the recommendation to monitor for additive sedation. "Moderate" does not mean ignore. It means the combination is acceptable in many patients with appropriate monitoring and counseling, not that the interaction is trivially safe without thought.

Sex-Specific Pharmacology: How Being a Woman Changes This Interaction

Women metabolize many CNS-active drugs differently from men, and hormonal status drives much of this variation. The following framework for thinking about this combination by life stage does not yet have a head-to-head trial behind it; the evidence is extrapolated from pharmacokinetic studies of each drug separately and from sex-differences literature.

Reproductive Years (Ages Approximately 18 to 45)

During the luteal phase of the menstrual cycle (days 14 to 28), progesterone rises. Progesterone and its neuroactive metabolite allopregnanolone are positive allosteric modulators of GABA-A receptors, producing a physiological CNS-depressant effect that is at its peak in the late luteal phase. A study in Neuropsychopharmacology confirmed that allopregnanolone levels correlate with subjective sedation and impaired psychomotor performance in healthy women. If you are taking gabapentin (which also acts on CNS calcium channels) and LDN together, your baseline CNS sensitivity peaks in the 10 days before your period. Sedation, dizziness, or coordination problems are most likely to emerge at that point in the cycle.

Perimenopause (Typically Ages 45 to 55)

Perimenopausal hormonal fluctuation is erratic rather than cyclical. Estrogen surges and drops unpredictably, and progesterone secretion becomes irregular. Sleep is already compromised for many perimenopausal women, with up to 60 percent reporting insomnia or sleep disruption. Gabapentin is sometimes prescribed for perimenopausal vasomotor symptoms and sleep, making the LDN-plus-gabapentin combination particularly common in this group. Monitoring is especially important here because the CNS baseline is already disrupted.

Postmenopause

Postmenopausal women face two compounding factors: lower estrogen (reducing CNS resilience) and age-associated decline in renal clearance. Both increase the effective exposure to gabapentin and LDN metabolites. Starting gabapentin at a lower dose (100 to 300 mg rather than the typical 300 mg starting dose) and titrating slowly is standard geriatric prescribing practice, and this principle applies to any postmenopausal woman combining it with LDN.

Women With PCOS

PCOS is associated with chronic low-grade inflammation and a higher prevalence of chronic pain conditions. LDN's anti-inflammatory mechanism makes it an area of active interest in PCOS. A small 2018 trial published in Fertility and Sterility found that LDN improved ovulatory frequency in women with PCOS who were clomiphene-resistant, though sample sizes were small and the finding is preliminary. Women with PCOS who are prescribed LDN for inflammatory modulation and separately prescribed gabapentin for pain should receive the same monitoring framework as any other patient, with particular attention to sleep quality, since both PCOS and gabapentin use affect sleep architecture.

Pregnancy, Lactation, and Contraception

This section is required reading if you are pregnant, trying to conceive, or breastfeeding.

Naltrexone in Pregnancy

Naltrexone is classified as FDA Pregnancy Category C, meaning animal studies have shown adverse fetal effects and there are no adequate, well-controlled human studies. LDN-specific human pregnancy data are extremely sparse. Case reports and small series exist, primarily from patients who continued naltrexone inadvertently before pregnancy recognition, but no prospective controlled trial has evaluated LDN in human pregnancy. Given this evidence gap, most prescribers discontinue LDN before conception attempts or as soon as pregnancy is confirmed.

Gabapentin in Pregnancy

Gabapentin's fetal risk data are more concerning. A 2020 cohort study in JAMA Internal Medicine found that gabapentin use in the first trimester was associated with a 1.6-fold increased risk of major congenital malformations, primarily cardiac septal defects, though absolute risk remained low. ACOG acknowledges the evolving data on gabapentin and advises that its use in pregnancy should be approached with caution and limited to cases where benefit clearly outweighs risk. Women of reproductive age on gabapentin should use reliable contraception if pregnancy is not desired, and a transition plan should be discussed with a prescriber before any planned conception.

Lactation

Naltrexone transfers into breast milk in small amounts. Published case data show low relative infant doses, estimated below 2 percent of the maternal dose, and no adverse infant outcomes have been reported in the limited cases documented. Gabapentin also transfers into breast milk; a pharmacokinetic study in breastfeeding women found average infant plasma levels of 1.3 to 4.0 micromol/L, with potential for infant sedation. Using both drugs together while breastfeeding adds the combined transfer risk. If either drug is clinically necessary during lactation, the infant should be monitored for sedation, feeding difficulty, and poor weight gain.

Contraception Requirements

Neither LDN nor gabapentin is a teratogen in the same category as, for example, valproate or isotretinoin, but the risk-benefit profile of both in pregnancy is unfavorable enough that reliable contraception is strongly recommended for women of reproductive age using either drug who are not actively trying to conceive. Discuss your contraception plan with your prescriber before starting either agent.

Who This Combination Is and Is Not Right For

Women Who May Be Appropriate Candidates

• Women with fibromyalgia already on gabapentin who have refractory inflammation or who want to reduce their overall gabapentin dose over time (LDN may allow partial dose reduction as pain control improves, though this has not been studied in a controlled trial)
• Women with endometriosis-related pain or autoimmune conditions where LDN's microglial modulation is the therapeutic target and gabapentin is managing neuropathic pain separately
• Women with normal renal function (eGFR above 60) who are not pregnant, not breastfeeding, and not on other CNS depressants

Women Who Should Proceed With Caution or Avoid This Combination

• Postmenopausal women with eGFR below 60 mL/min/1.73 m2 (dose adjustment for gabapentin is required; LDN metabolite clearance is also slowed)
• Women with obstructive sleep apnea, particularly those not using CPAP consistently
• Women concurrently using opioid analgesics (LDN at any dose will precipitate withdrawal in opioid-dependent patients; this is an absolute contraindication for LDN use, not just for the gabapentin combination)
• Women in the first trimester of pregnancy
• Women breastfeeding infants under 6 months without close infant monitoring

Monitoring, Dosing, and Practical Guidance

Starting the Combination Safely

If your clinician decides both drugs are appropriate, a stepwise approach reduces risk. Start one drug at a time so you can isolate which agent is causing any side effect. LDN is typically started at 1.5 mg nightly and titrated up to 4.5 mg over 4 to 12 weeks. Gabapentin is typically started at 100 to 300 mg and titrated based on response and tolerability. Taking LDN at bedtime (which is standard to align the transient opioid blockade with sleep hours and minimize vivid-dream complaints) means both drugs overlap in the overnight CNS-depressant window. If morning drowsiness is a problem, ask your prescriber whether shifting LDN to earlier in the evening or adjusting the gabapentin timing makes sense.

Renal Function Monitoring

A baseline creatinine or eGFR before starting this combination is reasonable clinical practice, particularly for women over 45 or those with hypertension, diabetes, or a PCOS-related metabolic profile (which increases chronic kidney disease risk). Recheck annually or if symptoms of drug accumulation appear (unusual sedation, balance problems, confusion).

Dose Adjustment for Renal Impairment

The gabapentin label specifies dose reductions at eGFR below 60 mL/min/1.73 m2: for eGFR 30 to 59, a maximum daily dose of 700 mg in divided doses is recommended. For eGFR 15 to 29, the maximum drops to 300 mg per day. These thresholds matter when LDN is present because both drugs are competing for the same excretory route, and impaired clearance of one amplifies the CNS effects of both.

Signs That the Combination Is Too Much

Call your prescriber promptly if you experience:

• Difficulty staying awake during the day despite adequate nighttime sleep
• New or worsening balance problems or falls
• Confusion or memory problems that were not present before
• Slowed or labored breathing, especially at night (ask a partner to observe if you can)
• Extreme muscle weakness

LDN's Broader Drug Interaction Profile in Women

Gabapentin is not the only drug interaction that matters for women using LDN. The following interactions are clinically relevant and frequently appear in women's-health contexts.

Opioid analgesics. LDN blocks mu-opioid receptors and will precipitate acute withdrawal in any woman who is opioid-dependent, including those on buprenorphine or methadone. This is an absolute contraindication, not a monitoring issue. The FDA naltrexone label explicitly warns against concurrent opioid use.

Antidepressants. Many women with fibromyalgia, endometriosis-related mood symptoms, or perimenopausal depression use SNRIs or SSRIs. These do not interact with LDN through CYP pathways, but duloxetine is itself used for fibromyalgia pain. Adding LDN to duloxetine is not contraindicated, but the combination has not been formally studied.

Hormonal contraceptives and hormone therapy. No pharmacokinetic interaction is documented between LDN and estrogen or progesterone-containing formulations. Women on combination oral contraceptives or menopausal hormone therapy do not need to change those regimens when starting LDN based on current evidence, though prescribers should document the combination.

Immunosuppressants. Women with autoimmune conditions such as lupus, Hashimoto thyroiditis, or multiple sclerosis may be on methotrexate, mycophenolate, or other immunosuppressants. LDN's immune-modulating effects are proposed, not fully characterized, and the interaction with formal immunosuppressive therapy is not well-studied. A 2018 clinical review in the Annals of Pharmacotherapy noted the lack of controlled trial data on LDN in autoimmune disease broadly, highlighting that much of the evidence base in this area is extrapolated from small studies or case series. Women in this situation should involve their rheumatologist or neurologist in the prescribing decision.

The Evidence Gap: What We Don't Know Yet

Women have historically been underrepresented in pain and neuropharmacology trials. The Younger et al. Fibromyalgia pilot trial that anchors much of the LDN literature enrolled a predominantly female sample (n=31), which is a strength for women's-health relevance but a limitation for statistical power. No randomized controlled trial has specifically examined the LDN-gabapentin combination. No pharmacokinetic study has characterized the interaction in postmenopausal women with reduced eGFR. The sedation signal from the interaction is inferred from each drug's individual CNS profile and from general drug interaction pharmacology, not from a dedicated combination study.

This honesty matters. If your clinician says the combination is "totally safe," they are extrapolating from indirect evidence, not citing a trial that proved it. "Extrapolated but biologically plausible" is a reasonable basis for a prescribing decision. It is not the same as "proven."